Glyceryl trinitrate in first-episode psychosis unmedicated with antipsychotics: A randomised controlled pilot study
dc.contributor.author | Merritt, Kate | |
dc.contributor.author | Catalán Alcántara, Ana | |
dc.contributor.author | Cowley, Samuel | |
dc.contributor.author | Demjaha, Arsime | |
dc.contributor.author | Taylor, Matthew | |
dc.contributor.author | McGuire, Philip | |
dc.contributor.author | Cooper, Ruth | |
dc.contributor.author | Morrison, Paul | |
dc.date.accessioned | 2020-10-23T12:21:16Z | |
dc.date.available | 2020-10-23T12:21:16Z | |
dc.date.issued | 2020-08 | |
dc.identifier.citation | Journal of psychopharmacology 34(8) : 839-847 (2020) | es_ES |
dc.identifier.issn | 0269-8811 | |
dc.identifier.issn | 1461-7285 | |
dc.identifier.uri | http://hdl.handle.net/10810/47265 | |
dc.description.abstract | There is a pressing need for new classes of treatment for psychosis. A key therapeutic target for novel compounds is the NMDA receptor, which may be modulated by nitric oxide donors such as sodium nitroprusside (SNP). Recent studies of SNP in patients with psychosis have mixed results, and the drug has to be administered intravenously. Glyceryl trinitrate (GTN) is a well-established cardiovascular medicine that is also a nitric oxide donor, and can be given orally. Aims: We explored the safety and potential effects of GTN in unmedicated patients with a first episode of psychosis. Methods: This was a single-centre, randomised, double-blind, placebo-controlled trial from December 2016 to April 2019 (ClinicalTrials.gov identifier: NCT02906553). Patients received 3 x sprays of GTN or placebo for three consecutive days, and were re-assessed on Days 1, 2, 3 and 7. The primary outcome was cognition (Jumping to Conclusions task), secondary outcomes were symptoms (Positive and Negative Syndrome Scale (PANSS)), verbal memory (Hopkins Verbal Learning task), and mood (Bond-Lader Visual Analogue Scales). Results: Nineteen patients were randomised, and 13 participants were included in the analyses. Compared with placebo, GTN was well tolerated, but was not associated with significant effects on cognition, symptoms, or mood. Bayesian statistics indicate that our results were 2x more likely under the null hypothesis than the alternative hypothesis, providing anecdotal evidence that GTN does not improve psychotic symptoms. Conclusions: We found no indication of an effect of GTN on symptoms of psychosis or cognition. Palabras clave | es_ES |
dc.description.sponsorship | The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by Guys & St Thomas' Charity grant (EFT150704) awarded to PM. The research was supported by the Department of Health via the National Institute for Health Research (NIHR) Specialist Biomedical Research Centre for Mental Health award to South London and Maudsley NHS Foundation Trust (SLaM) and the Institute of Psychiatry at King's College London, London. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Sage | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es/ | * |
dc.subject | clinical trial | es_ES |
dc.subject | psychosis | es_ES |
dc.subject | schizophrenia | es_ES |
dc.subject | sodium nitroprusside | es_ES |
dc.subject | glyceryl trinitrate sodium-nitroprusside | es_ES |
dc.subject | double-blind | es_ES |
dc.subject | placebo | es_ES |
dc.subject | symptoms | es_ES |
dc.subject | conclusions | es_ES |
dc.subject | medication | es_ES |
dc.subject | model | es_ES |
dc.title | Glyceryl trinitrate in first-episode psychosis unmedicated with antipsychotics: A randomised controlled pilot study | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). | es_ES |
dc.rights.holder | Atribución-NoComercial 3.0 España | * |
dc.relation.publisherversion | https://journals.sagepub.com/doi/10.1177/0269881120922967 | es_ES |
dc.identifier.doi | 10.1177/0269881120922967 | |
dc.departamentoes | Neurociencias | es_ES |
dc.departamentoeu | Neurozientziak | es_ES |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).